Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial  Endpoints NewsRoche unveils data behind BTK inhibitor’s phase 3 multiple sclerosis win in Ocrevus trial  Fierce BiotechACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial  Multiple Sclerosis News TodayGenentech plans NDA for multiple sclerosis pill with study win  BioWorld MedTechRO: Fenebrutinib matched ocrelizumab in PPMS efficacy and offers a promising oral high-efficacy MS option  TradingView